dipyridamole has been researched along with Labyrinth Diseases in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Labyrinth Diseases: Pathological processes of the inner ear (LABYRINTH) which contains the essential apparatus of hearing (COCHLEA) and balance (SEMICIRCULAR CANALS).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borasi, G | 1 |
| Pallestrini, EA | 1 |
| Sperati, G | 1 |
1 other study available for dipyridamole and Labyrinth Diseases
| Article | Year |
|---|---|
[The use of platelet aggregation-inhibiting drugs in central vestibular pathology caused by atherosclerotic vascular diseases].
Topics: Aspirin; Dipyridamole; Drug Evaluation; Humans; Intracranial Arteriosclerosis; Labyrinth Diseases; O | 1975 |